ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

https://oncologypro.esmo.org/Meeting-Resour...mparative-survival-and-disease-free-survival

Colorectal cancer is the third most common cancer in men and the second in women worldwide. Studies from different parts of the world have consistently reported a more advanced stage at presentation...

Date: 29 Jun 2016
Presenter: A. Hakim
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...estern-patients-with-resected-gastric-cancer

In Eastern oncologic centers, elevated carcino-embryonic antigen (CEA) has been found to be a harbinger of poor outcomes in the setting of resectable gastric cancer.

Date: 29 Jun 2016
Presenter: E. Greenleaf
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...oscopy-surveillance-and-risk-factor-analysis

There is a 1.5-5% annual incidence of synchronous esophageal cancer among head and neck squamous-cell carcinoma (HNSCC) patients, leading to a poorer overall survival rate.

Date: 29 Jun 2016
Presenter: L. Mei-Hsuan
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...nd-gastric-cancer-patients-and-their-outcome

The association of vitamin D deficiency with many chronic diseases worldwide is well known. Nevertheless, it has not been convincingly shown in randomised controlled trials that diseases can be controlled...

Date: 29 Jun 2016
Presenter: S. Thanthulage
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...tematic-review-of-81-epidemiological-studies

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and its incidence has increased during the past decade. While hepatitis B and C virus infections and alcohol are established...

Date: 29 Jun 2016
Presenter: O. Abdel-Rahman
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-in-Albania-a-hepatitis-B-virus-endemic-area

Albania remains a high hepatitis B virus endemic country, despite the evident reduction of HBsAg in the general non-vaccinated population from 18% to 9.5% after the implementation of the hepatitis B vaccination program (1).

Date: 29 Jun 2016
Presenter: F. Kraja
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...presenting-with-Hepatocellular-Carcinoma-HCC

The worldwide incidence of hepatocellular carcinoma (HCC) is increasing. The vast majority of cases occur in patients with underlying cirrhosis, and most patients present with disease that is too...

Date: 29 Jun 2016
Presenter: P. Spiliopoulou
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ence-and-sensitivity-to-MET-inhibitor-AMG337

Activation of the MET oncogene can result from amplification or activating mutation. MET mutations affecting the 14 5' splice acceptor site or the 3' splice donor site cause in-frame skipping of exon 14.

Date: 29 Jun 2016
Presenter: F. Cecchi
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-an-analysis-in-clinical-practice-experience

we know as the new biologicals therapies increase the overall survival (OS) and the progression free survival (PFS) compared with only conventional chemotherapy, but in our experience the use of...

Date: 29 Jun 2016
Presenter: S. Traverso Elena
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...olon-rectal-cancer-to-liver-improve-survival

Background: Colon-rectal cancer is the fourth most frequent cancer worldwide, unfortunately 35%–50% develop metastasis, 60%–80% of them have unresectable liver metastasis, 20% to 34% present with...

Date: 29 Jun 2016
Presenter: A. El-Nagar
Resources: Abstract